Phase 2 Crohn's Disease and Colitis Trial, RecruitingNCT06233461Sponsor: TakedaCondition: Crohn's Disease and Colitis
Printed from Voxsanity (voxsanity.com.au) — NCT06233461 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Phase 2 Crohn's Disease and Colitis Trial, Recruiting
NCT06233461
RecruitingPhase 2🇦🇺 Australian site
Who may be able to join
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People aged 18 to 75 years old (or 19 and older in South Korea) who have been diagnosed with Crohn's disease for at least 30 days
People whose Crohn's disease is considered moderately to severely active, based on specific medical scoring tests
People whose previous treatments for Crohn's disease did not work well enough, stopped working over time, or caused side effects they could not tolerate — this includes standard medications, biological therapies, or other advanced treatments
Who may not be able to join:
People diagnosed with certain other types of bowel or colon conditions, such as ulcerative colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, indeterminate colitis, or colitis related to diverticular disease
People who have Crohn's disease complications that are likely to require surgery during the study period
People who currently have a stoma (an opening on the abdomen connected to the digestive system)
People whose Crohn's disease has not responded to three or more different classes of advanced treatments
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Concord Repatriation General Hospital, Sydney, New South Wales
297676111
Mater Cancer Care Centre-Mater Health Services, South Brisbane, Queensland
731638196
Flinders Medical Centre, Bedford Park, South Australia
882044964
The Queen Elizabeth Hospital, Woodville, South Australia
882225827
Western Health/Footscray Hospital, Melbourne, Victoria
Harry Perkins Medical Research Institute Fiona Stanley Hospital, Murdoch, Western Australia
Royal Perth Hospital, Perth, Western Australia
Northern Hospital Epping, Epping,
Sir Charles Gairdner Hospital (SCGH) - Comprehensive Cancer Centre, Nedlands,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06233461
Sponsor: Takeda
Phase: Phase 2
Status: Recruiting
Condition: Crohn's Disease and Colitis
Trial contact: +1-877-825-3327
More information: https://clinicaltrials.gov/study/NCT06233461
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People aged 18 to 75 years old (or 19 and older in South Korea) who have been diagnosed with Crohn's disease for at least 30 days
People whose Crohn's disease is considered moderately to severely active, based on specific medical scoring tests
People whose previous treatments for Crohn's disease did not work well enough, stopped working over time, or caused side effects they could not tolerate — this includes standard medications, biological therapies, or other advanced treatments
Who may not be able to join:
People diagnosed with certain other types of bowel or colon conditions, such as ulcerative colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, indeterminate colitis, or colitis related to diverticular disease
People who have Crohn's disease complications that are likely to require surgery during the study period
People who currently have a stoma (an opening on the abdomen connected to the digestive system)
People whose Crohn's disease has not responded to three or more different classes of advanced treatments
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇺 Australia
🇧🇪 Belgium
🇧🇷 Brazil
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇳 China
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇳🇱 Netherlands
🇳🇴 Norway
🇵🇱 Poland
🇷🇴 Romania
🇸🇰 Slovakia
🇰🇷 South Korea
🇨🇭 Switzerland
🇹🇼 Taiwan
🇬🇧 United Kingdom
🇺🇸 United States
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Endoscopic Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.